Are you building an innovative and emerging life science or biotechstart-up?Now is your opportunity to accelerate your research and transform it into meaningful value for patients byapplying for an Astellas Future Innovator Prize.Astellas is o ering up to two Future Innovator Prizes for a pioneering science and technology platformthat would be a game-changing approach in Astellas’ interest areas including Blindness & Regeneration,Mitochondria Biology, Genetic Regulation, Immuno-Oncology, Cell Therapy, and other areas
The award for each Astellas Future Innovator Prize winner will:Cover the…
OXFORD, England, Nov. 18, 2021 /PRNewswire/ -- PharmaVentures is delighted to announce it has signed a Memorandum of Understanding (MOU) with the leading Korean investment bank, Shinhan Investment Corp Group & Global Investment Banking Group (SHIC). This MOU was signed by Adrian Dawkes, Managing Director at PharmaVentures and Keun Soo Chung, SHIC GIB Group Head, during an event last week at Seoul Yeouido SHIC tower, Seoul, South Korea.
Through this MOU, PharmaVentures and Shinhan Investment Corp intend to collaborate closely to provide a much broader range of capabilities and services to…
15 start-ups with huge potential have successfully completed the Data-driven Advanced Therapeutics Accelerator (DATA) programme at Stevenage Bioscience Catalyst (SBC), one of Europe’s most important science parks for life sciences. The course was tailored to give data-focused biotech start-ups the skills they need to get potential new drugs and therapies to market more quickly. It was supported by SBC’s community of biotech leaders who shared their expertise through this unique programme focused on the intersection of data analytics and drug discovery.
The programme was launched to seek out…
Cambridge, UK, 17th November 2021: Mursla, a liquid biopsy company, is pleased to announce the appointment of Professor Bernd Giebel, Dr Daniel Delubac and Professor Emmanuel Rautou to its Advisory Board.
Professor Bernd Giebel (PhD) is Professor at the University Duisburg-Essen. Highly experienced in the phenotypic characterisation of rare cells, (hematopoietic stem and progenitor cells), Bernd introduced Nanoparticle Tracking Analysis (NTA) to the scientific community as a quantification and size-measuring method for extracellular vesicles (EV) / exosomes in 2011. In the same year he…
A £375 million investment to improve understanding and treatment for a range of neurodegenerative diseases.Funding includes at least £50 million for motor neurone disease (MND) related research to find a cureNew National Institute for Health Research (NIHR) Motor Neurone Disease Research Unit to attract more innovative research applicationsPeople living with neurodegenerative diseases could live longer, healthier lives due to innovative new research, following a government commitment to invest £375 million over the next 5 years.
At least £50 million will be made available specifically for…
Drawing upon over 30-years’ experience of serving the glycobiology research community - AMSBIO has established a comprehensive portfolio of high-quality reagents including unique ranges of antibodies, lectins, enzymes, assay kits and standards, backed by in-depth technical support.Glycobiology (the study of the structure, biosynthesis, and biology of carbohydrates) is a complex and dynamic area of research that combines enzymology, molecular and cellular biology, organic chemistry and materials science. Widely acknowledged…
Boyds, the leading pharmaceutical and biotech product development consultancy, has announced the appointment of business development expert Dr Neil Fish to support the company as it embarks on the next stage of its global expansion.
With over 35 years’ experience in the life sciences industry and an outstanding track record of completing deals, Neil joins the Boyds team as Vice President of Business Development and will be responsible for supporting the company’s continued growth by developing its global client base.
Neil’s prior experience includes co-founding biotechnology start-up Alizyme…
tranScrip is delighted to announce that Dr Flic Gabbay has taken up office as the new President of the Faculty of Pharmaceutical Medicine (FPM). Flic, a co-founder of tranScrip, has spent 4 decades in drug development. Over the last 14 years, she has led tranScrip on multiple innovative projects and drug registrations for over 250 clients. Being elected President is particularly important to Flic as she Chaired the RCP London Steering Committee which founded FPM as part of the three UK Colleges of Physicians in 1989.Flic is an active Fellow of the Academy of Medical Science and is…
Cambridge and London, UK: 11 November 2021
One Nucleus, the not-for-profit Life Science membership group focused primarily on the Greater Cambridge and London Life Sciences Cluster, aims to enable that ecosystem to accelerate the translation of great science and innovation into better patient outcomes. One Nucleus supports companies throughout their life cycle. This includes facilitating engagement between members and expert research partners and providers of key services and insight.
BioIVT, a leading provider of high-quality biological specimens and related services globally, recently…
Cambridge and Liverpool, UK, 9 November 2021: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced a research collaboration with the Infection Innovation Consortium (iiCON), a global collaborative infectious disease R&D programme, to validate the next generation of COVID-19 research tools.
iiCON’s £174 million programme brings together industry, academia, and clinicians to accelerate the discovery, development and deployment of new treatments and products – saving and improving millions of…